CY1122983T1 - Νεες ενωσεις - Google Patents

Νεες ενωσεις

Info

Publication number
CY1122983T1
CY1122983T1 CY20201100536T CY201100536T CY1122983T1 CY 1122983 T1 CY1122983 T1 CY 1122983T1 CY 20201100536 T CY20201100536 T CY 20201100536T CY 201100536 T CY201100536 T CY 201100536T CY 1122983 T1 CY1122983 T1 CY 1122983T1
Authority
CY
Cyprus
Prior art keywords
relates
compounds
inhibitors
unions
new
Prior art date
Application number
CY20201100536T
Other languages
English (en)
Inventor
Alison Jones
Mark Ian Kemp
Martin Lee Stockley
Karl Richard Gibson
Gavin Alistair Whitlock
Andrew Madin
Original Assignee
Mission Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Limited filed Critical Mission Therapeutics Limited
Publication of CY1122983T1 publication Critical patent/CY1122983T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέες ενώσεις και μεθόδους για τη βιομηχανική κατασκευή αναστολέων ενζύμων αποουμπικουιτυλίωσης (DUBs). Συγκεκριμένα, η εφεύρεση αφορά στην αναστολή ουμπικουιτίνης C-τερματικής υδρολάσης L1 (UCHL1). Η εφεύρεση περαιτέρω αφορά στη χρήση αναστολέων DUB στη θεραπεία καρκίνου και άλλων ενδείξεων. Οι ενώσεις της εφεύρεσης περιλαμβάνουν ενώσεις που έχουν τον τύπο (Ι) ή φαρμακευτικώς αποδεκτό άλας αυτών, όπου R1 έως R8 είναι όπως ορίζονται στο παρόν.
CY20201100536T 2014-09-23 2020-06-11 Νεες ενωσεις CY1122983T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1416754.8A GB201416754D0 (en) 2014-09-23 2014-09-23 Novel compounds
PCT/GB2015/052729 WO2016046530A1 (en) 2014-09-23 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
CY1122983T1 true CY1122983T1 (el) 2021-10-29

Family

ID=51869322

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100536T CY1122983T1 (el) 2014-09-23 2020-06-11 Νεες ενωσεις

Country Status (23)

Country Link
US (5) US9926307B2 (el)
EP (2) EP3828179A1 (el)
JP (3) JP6549703B2 (el)
KR (1) KR102493967B1 (el)
CN (2) CN111592534B (el)
AU (1) AU2015323572B2 (el)
CA (1) CA2958262C (el)
CY (1) CY1122983T1 (el)
DK (1) DK3197883T3 (el)
ES (1) ES2798473T3 (el)
GB (1) GB201416754D0 (el)
HR (1) HRP20200962T1 (el)
HU (1) HUE050732T2 (el)
IL (1) IL250345B (el)
LT (1) LT3197883T (el)
MX (1) MX2017003358A (el)
PL (1) PL3197883T3 (el)
PT (1) PT3197883T (el)
RS (1) RS60468B1 (el)
RU (1) RU2691389C2 (el)
SG (1) SG11201700847YA (el)
SI (1) SI3197883T1 (el)
WO (1) WO2016046530A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015277786B2 (en) 2014-06-19 2019-04-18 Takeda Pharmaceutical Company Limited Heteroaryl compounds for kinase inhibition
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
RS61759B9 (sr) * 2015-03-30 2021-11-30 Mission Therapeutics Ltd Jedinjenja 1-cijano-pirolidina kao inhibitori usp30
CN107922386B (zh) * 2015-06-22 2021-04-02 大日本住友制药株式会社 1,4-二取代的咪唑衍生物
CN107849013B (zh) * 2015-07-14 2022-03-29 特殊治疗有限公司 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
WO2017184751A1 (en) * 2016-04-20 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing hypertension
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3519385B1 (en) * 2016-09-27 2020-11-18 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018148863A1 (zh) * 2017-02-14 2018-08-23 华东理工大学 N-(5-吗啉代噻唑-2-基)甲酰胺类化合物及其制备方法和用途
WO2018209132A1 (en) * 2017-05-10 2018-11-15 Cortexyme, Inc. Aminopyridine compounds and methods for the preparation and use thereof
GB201708652D0 (en) * 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3642196B1 (en) * 2017-06-20 2022-08-17 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as dub inhibitors
RS64035B1 (sr) * 2017-08-01 2023-04-28 Merck Patent Gmbh Derivati tiazolopiridina kao antagonisti receptora adenozina
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2019084497A1 (en) * 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
WO2019089835A1 (en) 2017-10-31 2019-05-09 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
AR114422A1 (es) 2018-03-30 2020-09-02 Syngenta Participations Ag Compuestos herbicidas
KR20210010887A (ko) * 2018-05-17 2021-01-28 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 펩티다제 30 억제제로서 유용한 융합된 비시클릭 화합물
US20210179628A1 (en) * 2018-08-09 2021-06-17 Valo Early Discovery, Inc. Inhibiting deubiquitinase usp25 and usp28
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
EP4218934A1 (en) 2018-10-05 2023-08-02 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
KR102397752B1 (ko) * 2019-06-19 2022-05-16 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
EP4132925A1 (en) 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
CN115667252A (zh) 2020-05-28 2023-01-31 特殊治疗有限公司 用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
AU2021285130A1 (en) 2020-06-04 2023-01-19 Mission Therapeutics Limited N-cyanopyrrolidines with activity as USP30 inhibitors
BR112022024794A2 (pt) 2020-06-08 2022-12-27 Mission Therapeutics Ltd Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
TW202402754A (zh) * 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物
AU2022317661A1 (en) * 2021-07-26 2024-01-18 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
CA2404630A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
US7563788B2 (en) 2004-03-19 2009-07-21 Pfizer Inc. Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
WO2010052222A1 (en) 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
DK2780326T3 (en) * 2011-10-19 2019-03-04 Vivolux Ab PROCEDURE FOR INHIBITING DEUBIQUITINATION ACTIVITY
EP2874997A4 (en) 2012-07-19 2016-01-06 Univ Drexel NEW SIGMA RECEPTOR LIGANDS AND METHOD FOR REGULATING CELLULAR PROTEIN HOMEOSTASIS THEREWITH
CA2909964A1 (en) 2013-05-02 2014-11-06 E3X Bio Method for identifying modulators of ubiquitin ligases
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
RS61759B9 (sr) 2015-03-30 2021-11-30 Mission Therapeutics Ltd Jedinjenja 1-cijano-pirolidina kao inhibitori usp30
CN107849013B (zh) 2015-07-14 2022-03-29 特殊治疗有限公司 作为dub抑制剂用于治疗癌症的氰基吡咯烷类

Also Published As

Publication number Publication date
CA2958262A1 (en) 2016-03-31
JP2019178161A (ja) 2019-10-17
RU2017105296A3 (el) 2019-01-22
US11993595B2 (en) 2024-05-28
JP2017530960A (ja) 2017-10-19
ES2798473T3 (es) 2020-12-11
US20200369658A1 (en) 2020-11-26
US10392380B2 (en) 2019-08-27
HUE050732T2 (hu) 2021-01-28
GB201416754D0 (en) 2014-11-05
US20190330202A1 (en) 2019-10-31
US11472798B2 (en) 2022-10-18
CN111592534A (zh) 2020-08-28
MX2017003358A (es) 2017-09-13
WO2016046530A1 (en) 2016-03-31
JP6959299B2 (ja) 2021-11-02
IL250345B (en) 2019-05-30
CN107001339B (zh) 2020-03-17
EP3197883A1 (en) 2017-08-02
DK3197883T3 (da) 2020-06-22
US9926307B2 (en) 2018-03-27
CN107001339A (zh) 2017-08-01
PL3197883T3 (pl) 2020-10-19
US20230052191A1 (en) 2023-02-16
US20180162852A1 (en) 2018-06-14
PT3197883T (pt) 2020-06-22
IL250345A0 (en) 2017-03-30
EP3828179A1 (en) 2021-06-02
CN111592534B (zh) 2023-06-30
JP6549703B2 (ja) 2019-07-24
LT3197883T (lt) 2020-07-10
SG11201700847YA (en) 2017-04-27
AU2015323572A1 (en) 2017-03-23
US10774078B2 (en) 2020-09-15
EP3197883B1 (en) 2020-03-18
AU2015323572B2 (en) 2019-09-19
HRP20200962T1 (hr) 2020-10-02
BR112017005887A2 (pt) 2017-12-12
KR20170055499A (ko) 2017-05-19
SI3197883T1 (sl) 2020-08-31
CA2958262C (en) 2023-02-14
JP7261264B2 (ja) 2023-04-19
RS60468B1 (sr) 2020-07-31
JP2021138734A (ja) 2021-09-16
KR102493967B1 (ko) 2023-01-31
RU2017105296A (ru) 2018-10-24
US20170247365A1 (en) 2017-08-31
RU2691389C2 (ru) 2019-06-13

Similar Documents

Publication Publication Date Title
CY1122983T1 (el) Νεες ενωσεις
CY1124170T1 (el) Ενωσεις 1-κυανο-πυρρολιδινης ως αναστολεις usp30
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1123906T1 (el) Αναστολεις απομεθυλασης ιστονης
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
WO2017109488A8 (en) Cyanopyrrolidine derivatives as inhibitors for dubs
CY1119422T1 (el) Παραγωγα μπετουλινης
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201691421A1 (ru) Гетероарилы и их применение
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MX2017003464A (es) Inhibidores de histona desmetilasa.
CY1118371T1 (el) Αναστολεις του iap
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MX2016008499A (es) Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).
MX2017005423A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MY193239A (en) Novel b-lactamase inhibitors